West Pharmaceutical Services, Inc. (WST): Price and Financial Metrics
West Pharmaceutical Services, Inc. (WST)
Today's Latest Price: $281.64 USD
Updated Oct 28 2:31pm
Add WST to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 142 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
WST Stock Summary
- West Pharmaceutical Services Inc's market capitalization of $20,707,744,631 is ahead of 90.69% of US-listed equities.
- West Pharmaceutical Services Inc's stock had its IPO on January 5, 1988, making it an older stock than 89.3% of US equities in our set.
- Price to trailing twelve month operating cash flow for WST is currently 48.14, higher than 92.37% of US stocks with positive operating cash flow.
- If you're looking for stocks that are quantitatively similar to West Pharmaceutical Services Inc, a group of peers worth examining would be PAYC, TECH, MKTX, LOGI, and HAE.
- WST's SEC filings can be seen here. And to visit West Pharmaceutical Services Inc's official web site, go to www.westpharma.com.
WST Stock Price Chart Interactive Chart >
WST Price/Volume Stats
| Current price | $281.64 | 52-week high | $303.14 |
| Prev. close | $286.07 | 52-week low | $124.53 |
| Day low | $276.40 | Volume | 313,320 |
| Day high | $284.26 | Avg. volume | 609,046 |
| 50-day MA | $279.50 | Dividend yield | 0.22% |
| 200-day MA | $216.17 | Market Cap | 20.82B |
West Pharmaceutical Services, Inc. (WST) Company Bio
West Pharmaceutical Services develops, manufactures, and sells components and systems for the packaging and delivery of injectable drugs, as well as delivery system components for the pharmaceutical, healthcare, and consumer products industries. The company operates through two segments, Pharmaceutical Packaging Systems and Pharmaceutical Delivery Systems. The company was founded in 1923 and is based in Exton, Pennsylvania.
WST Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $281.64 | $91.57 | -67% |
Below please find a table outlining a discounted cash flow forecast for WST, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that West Pharmaceutical Services Inc ranked in the 22th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 67.17%. As for the metrics that stood out in our discounted cash flow analysis of West Pharmaceutical Services Inc, consider:
- Interest coverage, a measure of earnings relative to interest payments, is 47.38 -- which is good for besting 92.38% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
- The business' balance sheet reveals debt to be 2% of the company's capital (with equity being the remaining amount). Approximately merely 7.13% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- WST's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 50.75% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -68% |
| 1% | -68% |
| 2% | -67% |
| 3% | -67% |
| 4% | -67% |
| 5% | -66% |
GMED, OFIX, TMO, ABT, and BAX can be thought of as valuation peers to WST, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...